Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors
Exploratory Study of a Novel Dual Target Molecular Probe NI-FAPI-04 for Intra Irradiation Therapy of Hypoxic and Fibroblast Activation Protein Related Tumors
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Age between 18-80 years old
- Obtain pathological results through surgery or biopsy
- Loss of surgical opportunity (distant metastasis, or unsuitability for surgery due to contraindications); The condition still progresses after conventional chemotherapy, radiotherapy, targeted drug therapy, and other treatments (according to RECIST/PERCAST criteria)
- Expected survival time greater than 6 months
- Baseline [68Ga] Ga-NI-FAPI-04 PET/CT imaging reveals high uptake lesions
- Informed consent and the ability to accept follow-up
- Bone marrow reserve: neutrophil count ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; hemoglobin ≥ 90 g/L
- Liver function: AST/ALT ≤ 3 × ULN, or subjects with liver metastasis<5 × ULN; Albumin>3.0 g/dL; Total bilirubin ≤ 1.5 × ULN
- Renal function: creatinine clearance rate ≥ 50 mL/min
- Coagulation function: INR ≤ 1.5 (for patients who have not received warfarin treatment); Prothrombin time (PTT)<2 × ULN
Exclusion Criteria:
- Pregnant and lactating female patients
- Individuals who fear confinement or radiation
- Individuals who have received systemic anti-tumor treatment, including chemotherapy or curative radiotherapy, within 4 weeks prior to their first medication, or who have received TKI treatment within 2 weeks
- Patients treated with isotopes such as strontium-89, samarium-153, rhenium 186, rhenium 188, radium-223, etc. within 6 months
- Individuals who have experienced severe allergic reactions to the components of [177Lu] Lu-NI-FAPI-04 injection in the past
- Received any investigational medication within 28 days prior to the first dose, or participated in another clinical study at the same time (except for those who participated in observational, non interventional clinical studies, or are currently in the follow-up period of interventional clinical studies)
- Patients who are difficult to receive further diagnosis and treatment due to severe illness
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: NI-FAPI group
Injection of [177Lu]Lu-NI-FAPI
|
Subjects were injected with 177Lu-NI-FAPI at 60mCi or 120mCi.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tidsramme: 6-8 weeks after administration
|
According to CTCAE v5.0, the number of patients who experienced adverse events was counted
|
6-8 weeks after administration
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Visual analysis of PET images before and after treatment
Tidsramme: 6-8 weeks after administration
|
Describe the location of the lesion
|
6-8 weeks after administration
|
|
The size of the lesion before and after treatment
Tidsramme: 6-8 weeks after administration
|
Measure the size of the lesion(cm)
|
6-8 weeks after administration
|
|
The degree of uptake of the lesion before and after treatment
Tidsramme: 6-8 weeks after administration
|
Semi-quantitative analysis of changes in lesion uptake (SUVmax) before and after treatment
|
6-8 weeks after administration
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate of [177Lu] Lu-NI-FAPI-04
Tidsramme: 6-8 weeks after administration
|
Compare [68Ga] Ga-NI-FAPI-04 PET/CT and [18F] FDG PET/CT with baseline PET imaging after standardized dose treatment, and count the number of patients with objective responses and calculate the objective response rate
|
6-8 weeks after administration
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- I-25PJ0466
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .